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Convergence of cMyc and b-catenin on Tcf7l1
enables endoderm specification
Gillian Morrison1,†,*, Roberta Scognamiglio2,3, Andreas Trumpp2,3 & Austin Smith1,4,**
Abstract
The molecular machinery that directs formation of definitive endo-
derm from pluripotent stem cells is not well understood. Wnt/
b-catenin and Nodal signalling have been implicated, but the
requirements for lineage specification remain incompletely
defined. Here, we demonstrate a potent effect of inhibiting glyco-
gen synthase kinase 3 (GSK3) on definitive endoderm production.
We find that downstream of GSK3 inhibition, elevated cMyc and
b-catenin act in parallel to reduce transcription and DNA binding,
respectively, of the transcriptional repressor Tcf7l1. Tcf7l1
represses FoxA2, a pioneer factor for endoderm specification. Dele-
tion of Tcf7l1 is sufficient to allow upregulation of FoxA2 in the
presence of Activin. In wild-type cells, cMyc contributes by reduc-
ing Tcf7l1 mRNA, while b-catenin acts on Tcf7l1 protein. GSK3 inhi-
bition is further required for consolidation of endodermal fate via
upregulation of Sox17, highlighting sequential roles for Wnt signal-
ling. The identification of a cMyc/b-catenin-Tcf7l1-FoxA2 axis
reveals a de-repression mechanism underlying endoderm induction
that may be recapitulated in other developmental and patho-
logical contexts.
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Introduction
Nodal/Activin signalling is required for endoderm specification in
the embryo (Brennan et al, 2001; Vincent et al, 2003) and steering
differentiation of pluripotent stem cells towards definitive endo-
derm (Kubo et al, 2004; Gadue et al, 2006; Morrison et al, 2008).
Canonical Wnt signalling is also implicated in the formation of
endoderm and mesoderm during early development (Liu et al,
1999; Huelsken et al, 2000; Tsakiridis et al, 2014) and can
enhance expression of primitive streak-associated genes in
differentiating embryonic stem (ES) cells (Gadue et al, 2006; ten
Berge et al, 2008).
The transcription factor FoxA2 is the earliest known marker of
definitive endoderm. Its upregulation at the onset of gastrulation
is considered to represent a crucial step in commitment to
definitive endoderm identity (Levinson-Dushnik & Benvenisty, 1997;
Burtscher & Lickert, 2009). Surprisingly, we have a limited under-
standing of the signalling processes that activate FoxA2 expression
and initiate molecular specification of definitive endoderm.
Mouse ES cells are pluripotent cell lines with a capacity to dif-
ferentiate into all cell types of the developing and adult organism
(Bradley et al, 1984; Smith, 2001). The heterogeneity of ES cells
maintained in the presence of serum (Hayashi et al, 2008; Silva &
Smith, 2008) can be a confounding factor when attempting to
optimise lineage specification and delineate initial molecular and
cellular transitions. ES cells can, however, be maintained as a
substantially homogeneous population of naı¨ve stem cells when
cultured without serum in the presence of inhibitors of both MEK/
Erk signalling and glycogen synthase kinase-3; termed “2i” (Ying
et al, 2008; Wray et al, 2010). Upon release from the naı¨ve ground
state conditions, ES cells readily undergo developmental progression
and lineage specification (Hayashi et al, 2011; Marks et al, 2012;
Betschinger et al, 2013; Buecker et al, 2014; Kalkan & Smith, 2014;
Yang et al, 2014).
Here, we exploit the experimental tractability of ground state ES
cell differentiation to explore molecular events that link signalling
processes with transcriptional changes during acquisition of defini-
tive endoderm identity. In particular, we focus on pivotal events
downstream of inhibition of GSK3.
Results
Suppression of GSK3 activity during exit from naïve pluripotency
promotes endoderm lineage specification
We first examined the response of naı¨ve ES cells to a well-
established cocktail of endoderm differentiation inducers (Kubo
et al, 2004; Gadue et al, 2006; McLean et al, 2007; Morrison et al,
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2008)(Activin, FGF4, heparin and PI3K inhibitor) in conjunction
with withdrawal from 2i. We detected only a minor increase in the
number of cells expressing the endoderm markers CXCR4 and
Sox17 after 7 days (Fig 1A). Therefore, Activin is not sufficient to
drive naı¨ve pluripotent cells into the endoderm lineage. Previous
studies have suggested that endoderm may be increased in response
to Wnt signalling or GSK3 inhibition (D’Amour et al, 2005; Gadue
et al, 2006; Bone et al, 2011; Loh et al, 2014). We therefore applied
the GSK3 inhibitor CHIR99021 (CH) in combination with the other
factors (Fig EV1). This resulted in a striking and reproducible
increase in the proportion of cells positive for CXCR4 from < 15% to
~80% (Fig 1A). A similar result was observed for Sox17 immuno-
staining (Fig 1A).
Gene expression analysis confirmed that Sox17, Hex and addi-
tional endoderm markers were significantly upregulated (Fig 1B).
Mesodermal and neural markers were not induced, and ES cell
pluripotency markers Oct4 and Nanog were downregulated
(Fig 1B). Co-staining for E-cadherin and FoxA2 at day 7 of differen-
tiation provided further evidence of efficient production of endo-
dermal cells in the presence of CH (Fig 1C). Extraembryonic
endoderm markers Sox7 and AFP were not expressed and less than
ten per cent of cells were positive for PDGFRa at day 7, a marker
of both extraembryonic endoderm and mesoderm (Fig EV1). The
differentiation process displayed a sequence of gene expression
changes that mirror those observed in early mouse development
(Arnold & Robertson, 2009) with the primitive streak/early endo-
derm marker CXCR4 detected at day 2–3 and Sox17 from day 4
(Fig 1D and E).
To investigate which events are affected by GSK3 inhibition in
the context of endoderm inductive conditions, a time-course analy-
sis of marker gene expression was performed (Fig EV1). Downregu-
lation of the naı¨ve pluripotency marker Nanog was slightly delayed
by GSK3 inhibition consistent with the known effects on self-
renewal circuitry (Martello et al, 2012). Upregulation of the early
primitive streak markers Tbra and Wnt3 at 24–48 h is promoted by
GSK3 inhibition, but the most potent effect is on the induction of
the key early definitive endoderm marker FoxA2; CH is a require-
ment for induction of FoxA2 as ES cells exit the naı¨ve state.
By administering pulses of CH treatment, we found that GSK3
inhibition is critical for endoderm differentiation between days 1–5
(Fig EV1). Withdrawal of CH after induction of early primitive
streak cells (Tbra/Wnt3 positive) at day 2 was not sufficient for
emergence of endoderm cells. Similarly, removal of CH at day 3
following induction of FoxA2 did not allow Sox17 expression. We
conclude that the inclusion of GSK3 inhibitor throughout this dif-
ferentiation regime promotes the successive emergence of early
primitive streak-like cells and definitive endoderm.
Five alternative inhibitors with distinct chemical structures
yielded a similar production of endoderm as CH (Fig EV1), strongly
indicating that the effect is mediated specifically through GSK3 inhi-
bition. Importantly, Activin was essential for appreciable induction
of endoderm markers (Fig EV1). Fgf4, heparin and the PI3K inhi-
bitor PI103 were each partially dispensable, but collectively substan-
tially increased the final yield (Fig EV1).
We tested five different ES cell lines, including one derived from
NOD mice (a background genetically distinct from conventional
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Figure 1. Suppression of GSK3 activity promotes endoderm production from naïve ES cells.
A Quantification of CXCR4+ cells by flow cytometry and Sox17+ cells by immunostaining at day 7 following differentiation in the presence or absence of 3 lM CH.
Average and standard deviation (SD) of eight independent experiments.
B Gene expression profiling by RT–PCR at day 7 of differentiation. Average and SD of three independent experiments.
C Immunostaining for E-cadherin (left) and FoxA2 (right) at day 7 of differentiation in the presence of 3 lM CH. Scale bars, 200 lm.
D Quantification of CXCR4+ by flow cytometry over a 7-day differentiation time course in the presence of 3 lM CH. Average and SD of three independent experiments.
E Immunostaining for Sox17 at day 4 to day 7 of differentiation in the continuous presence or absence of 3 lM CH. Scale bars, 200 lm.
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strain 129 ES cells). All produced > 70% Sox17+ cells on day 7 of
differentiation (Fig EV1), demonstrating reproducibility of this
protocol. Induced endodermal cells were able to differentiate further
on application of established protocols (D’Amour et al, 2005;
Morrison et al, 2008) for generation of pancreatic and hepatic
progenitors (Fig EV1).
Collectively, these findings demonstrate that inhibition of GSK3
facilitates formation of definitive endoderm from naı¨ve ES cells in
response to Nodal/Activin.
GSK3 inhibition reduces expression of the transcriptional
repressor Tcf7l1 (Tcf3)
We investigated candidate pathways through which inhibition of
GSK3 might relieve a roadblock to definitive endoderm. GSK3 inhi-
bition has been demonstrated to reduce activity of the transcrip-
tional repressor Tcf7l1 (also known as Tcf3) in undifferentiated ES
cells (Wray et al, 2011; Yi et al, 2011; Martello et al, 2012). We
reasoned that under differentiation conditions, CH might facilitate
endodermal specification by de-repression of additional Tcf7l1
targets. We examined expression of Tcf7l1 during the early phase of
endodermal differentiation and found that Tcf7l1 mRNA was
reduced approximately twofold in the presence of CH (Fig 2A).
Levels of Tcf7l1 protein were even more severely affected (Fig 2B).
The decrease in Tcf7l1 preceded an increase in expression of the
earliest endodermal gene FoxA2 (Fig 2C).
GSK3 inhibition reduces binding of Tcf7l1 to the FoxA2 gene locus
Using the CODEX compendium of ES cell ChIP-Seq data sets
(Sa´nchez-Castillo et al, 2015), we surveyed a range of candidate
regulators of the endoderm lineage to search for potential direct
transcriptional targets of Tcf7l1. Binding peaks were identified in
the region of several genes associated with early endodermal dif-
ferentiation, including FoxA2, Nodal and Eomesodermin (Fig 2D). A
single Tcf7l1 binding peak identified at the FoxA2 locus is located
within a 250-bp region that is highly conserved within mammals
(Fig EV2). Two TCF/LEF consensus DNA-binding motifs (van Beest
et al, 2000) are present within this binding peak (Fig EV2).
ChIP-PCR on wild-type and Tcf7l1 null ES cells confirmed speci-
fic binding of Tcf7l1 to the FoxA2 locus at similar levels to that
observed for Klf2, a previously validated target (Martello et al,
2012). Significant binding was also validated at Eomes (Fig 2E).
Strikingly, inclusion of CH during differentiation significantly
reduced Tcf7l1 binding to the FoxA2 locus at day 3 compared to
cells without CH (Fig 2F). Diminished Tcf7l1 binding correlates
with the early increase in FoxA2 expression (Fig 2C). We surmise
that removal of direct transcriptional repression of FoxA2 by Tcf7l1
may be an initiating molecular event in the emergence of endo-
dermal identity and can be triggered by pharmacological inhibitors
of GSK3.
Tcf7l1 null ES cells do not require CH to initiate
endodermal differentiation
To examine this hypothesis, we tested whether elimination of Tcf7l1
could replace the requirement for CH in the induction of endoderm.
Tcf7l1 null cells exhibit a general delay in entry into differentiation
due to sustained expression of the pluripotency gene regulatory
network (Pereira et al, 2006; Guo et al, 2011; Martello et al, 2012;
Betschinger et al, 2013). Consistent with this, FoxA2 was not fully
upregulated until day 4, approximately 24 h later than in wild-type
control cells (Fig 3A). Strikingly, however, at day 4 of differentia-
tion, the expression of FoxA2 in Tcf7l1 null cells without CH was
equal to or higher than that in wild-type cells with CH (Fig 3B).
Genetic ablation of Tcf7l1 therefore renders FoxA2 induction inde-
pendent of GSK3.
Eomesodermin and Cerl1, markers of nascent endoderm, were
also induced in Tcf7l1 null cells without CH (Fig 3B). FoxA2 protein
was also detected (Fig 3C). However, although Sox17 and other
endodermal marker genes that are upregulated later than FoxA2
(e.g. CXCR4 and Hex) were expressed at higher levels in Tcf7l1 null
cells than in control cells without CH, levels did not reach those in
cells treated with CH (Fig 3D). Thus, absence of Tcf7l1 removes the
requirement for inhibition of GSK3 for initial, but not later, stages of
endodermal lineage specification.
Induction of FoxA2 as cells exit pluripotency can replace GSK3
inhibition in enabling endoderm specification
The preceding data indicate that the critical response to CH treat-
ment during early differentiation is to relieve Tcf7l1 repression of
FoxA2. A prediction of such a model is that forced expression of
FoxA2 would be sufficient to trigger endodermal specification in the
absence of CH. To test this, we generated two independent ES cell
lines containing a doxycycline-inducible FoxA2 transgene. Addition
of doxycycline (DOX) increased FoxA2 mRNA and protein, but was
insufficient to impose endodermal differentiation under self-renewal
conditions (2i) when other inputs are blocked (Fig 4A and B). Under
differentiation permissive conditions, addition of DOX resulted in
expression of the endoderm marker CXCR4 by day 3 without
requirement for CH (Fig 4C). We noted, however, that few Sox17-
positive cells were obtained in the continued absence of CH
(Fig 4D). We therefore added CH at day 4, following induction of
FoxA2. Equivalent numbers of Sox17 cells were obtained as from
cultures in CH from day 0 to 7 (Fig 4D and E). Importantly, Sox17
could only be induced by late addition of CH if this was preceded by
early FoxA2 induction; FoxA2 induction after day 3 resulted in very
few Sox17 cells. These observations are consistent with sequential
and mechanistically distinct roles for CH; early FoxA2 induction via
de-repression of Tcf7l1, and subsequent upregulation of Sox17 to
consolidate definitive endoderm identity, likely involving b-catenin-
mediated transcriptional activation via other Lef/Tcf family
members.
Downregulation of Tcf7l1 occurs independently of Wnt/b-catenin
We examined substrates of GSK3 that might explain the downregu-
lation of Tcf7l1. GSK3 has pleotropic roles as a negative regulator
of diverse pathways and processes (Doble, 2003) and is a well-
established regulatory component of the canonical Wnt/b-catenin
signalling pathway. A direct protein–protein interaction between
Tcf7l1 and b-catenin has been documented (Hikasa & Sokol, 2011;
Shy et al, 2013). We therefore anticipated that the effects of CH on
endoderm induction may be attributable to recapitulation of Wnt/
b-catenin signalling.
ª 2015 The Authors The EMBO Journal
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Recombinant Wnt3a (200 ng/ml, in the presence of 500 ng/ml
R-spondin-1) induced a similar activation of the TOPFlash reporter
as 3 lM CH during endodermal differentiation (Fig 5A). However,
this treatment had no influence on Tcf7l1 mRNA expression and
resulted in substantially lower induction of FoxA2 than obtained
with CH (Fig 5B). Increasing doses of Wnt3a had no greater effect.
These data indicate that Wnt3a can only partially reproduce the
effect of CH.
To address directly whether the canonical Wnt/b-catenin is
necessary for activation of FoxA2, we used Ctnnb1 (b-catenin) null
ES cells (Wray et al, 2011). We found that Ctnnb1 null cells
displayed downregulation of Tcf7l1 protein and upregulation of
FoxA2 in a CH-dependent manner, albeit to a lower extent that
control cells (Fig 5C and D). They also showed reduced Tcf7l1
mRNA expression in response to CH (Fig 5C). Null cells did not
progress further in differentiation, in line with the requirement for
b-catenin in epithelialisation (Lyashenko et al, 2011).
These findings suggests that function for b-catenin is more in
consolidation of definitive endoderm lineage commitment than
initial specification via induction of FoxA2, which may proceed
independently. Consistent with this, we found that inhibition of
Wnt/b-catenin signalling using the tankyrase inhibitor XAV-939
(Huang et al, 2009) did not prevent the down regulation of Tcf7l1
and had little effect on FoxA2 expression (Fig EV3) but prevented
upregulation of Sox17.
GSK3 inhibition stabilises cMyc, which suppresses
Tcf7l1 expression
cMyc is a well-known target of GSK3 inhibition. GSK3 phosphory-
lates cMyc at Thr58 and thereby triggers degradation of the protein
(Sears et al, 2000; Yeh et al, 2004). GSK3 inhibition during ES cell
differentiation may therefore be predicted to result in stabilisation of
cMyc. We explored whether increased levels of cMyc may play a
role in attenuation of Tcf7l1.
cMyc expression is low or undetectable in naı¨ve ES cells (Ying
et al, 2008; Marks et al, 2012) and has been shown to be dispens-
able for self-renewal (Davis et al, 1993; Hishida et al, 2011). cMyc
transcription was dramatically increased > 100-fold upon induction
of endodermal differentiation (Fig 6A). Total cMyc protein also
increased, peaking at day 3 of differentiation (Fig 6B). Phosphoryla-
tion of cMyc at serine 62 (pSer62) is commonly associated with
A B
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Figure 2. GSK3 inhibition reduces activity of the transcriptional repressor Tcf7l1.
A Assay of Tcf7l1 mRNA by RT–PCR for the first 4 days of differentiation in the presence or absence of 3 lM CH. Average and SD of three independent experiments.
Day 2: *P = 0.048, Day 3: *P = 0.036.
B Immunoblot for Tcf7l1 at day 3 of differentiation in the presence (+) or absence () of 3 lM CH. Tubulin was used as a loading control.
C Assay of FoxA2 mRNA by RT–PCR for the first 3 days of differentiation in the presence or absence of 3 lM CH. Average and SD of three independent experiments.
**P = 5 × 107.
D ChIP-seq data from a compendium of transcription factor ChIP-seq analyses (Sánchez-Castillo et al, 2015). Gene tracks represent binding of Tcf7l1 at the FoxA2, Nodal
and Eomesodermin (Eomes) gene locus. Red lines indicate the regions analysed by ChIP-PCR for Tcf7l1.
E ChIP for Tcf7l1 followed by qPCR for the regions indicated in (D). Analysis was performed in wild-type ES cells in 2i culture conditions. Average and SD of three
independent experiments. Klf2: *P = 0.025, FoxA2: *P = 0.050, Eomes. *P = 0.023.
F ChIP for Tcf7l1 followed by qPCR. Analysis was performed in wild-type ES cells on day 3 of differentiation in the presence or absence of 3 lM CH. Average and SD of
three independent experiments. FoxA2: *P = 0.049.
Source data are available online for this figure.
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stabilisation of cMyc (Sears et al, 2000), and levels of both pSer62
cMyc and total cMyc were increased by GSK3 inhibition with the
ratio of pSer62 cMyc/total cMyc remaining constant during differen-
tiation (Fig 6B). In contrast, the level of phosphorylation of cMyc at
Thr68 (pThr58) decreased significantly in the presence of CH, with
the ratio of pThr58/total protein being very low at day 2 and 3 of
differentiation (Fig 6C). Without GSK3 inhibition, the ratio of
pThr58/total protein was very much increased and the levels of total
cMyc were lower. Similar results for total cMyc and pThr68 cMyc
were observed in Ctnnb1 null cells (Fig 6D), indicating this effect of
CH on cMyc is independent of Wnt/b-catenin signalling. These data
confirm that CH treatment increases stabilisation and accumulation
of cMyc immediately prior to FoxA2 induction.
NMyc is closely related to cMyc, dimerises with Max, and can
compensate for loss of cMyc (Lu¨scher & Larsson, 1999; Malynn
et al, 2000). Since NMyc also appears to be a target of GSK3
(Kenney et al, 2004; Sjostrom et al, 2005), we examined its
expression profile. NMyc transcript was detectable in naı¨ve ES cells
and increased in CH-treated cultures at day 3 of differentiation
(Fig EV4).
Both cMyc and NMyc form a specific DNA-binding complex with
a partner protein termed Max. Though typically associated with
gene activation, Myc/Max can also repress genes by binding to their
promoters in association with Miz1 (Staller et al, 2001; Gebhardt
et al, 2006; Herkert & Eilers, 2010; van Riggelen et al, 2010; Walz
et al, 2014). Strikingly, pharmacological inhibitors (cMyc inhibitor
II (Calbiochem) and 10058-F4 (Sigma)) that prevent the Myc/Max
interaction (Zirath et al, 2013; Mu¨ller et al, 2014) significantly
reduced the ability of CH to repress Tcf7l1 expression during dif-
ferentiation (Fig 6E), providing evidence that the effect of CH on
Tcf7l1 transcription is mediated through Myc proteins.
To confirm the requirement for Myc proteins, we analysed cells
genetically deleted for cMyc. These cells also have reduced levels of
nMyc following deletion of one allele (cMyc/;nMyc+/) (manu-
script submitted). In these Myc-deficient cells, the decrease in Tcf7l1
transcript we observe in response to CH in wild-type cells is lost
(Fig 6F). Furthermore, FoxA2 is not induced at the transcript or
protein level (Fig 6F and G). These data provide genetic evidence
that Myc plays a key role in the specification of endoderm from
naı¨ve ES cells.
We then investigated whether stabilised cMyc could replace
GSK3 inhibition. cMycT58A is a stabilised version of cMyc insensi-
tive to GSK3 phosphorylation (Gregory et al, 2003). We generated
ES cell lines containing a doxycycline (Dox)-inducible cMycT58A
transgene (iT58A lines). cMyc mRNA was increased 24 h following
Dox induction in a dose-dependent manner (Fig 6H). Moderate
induction of cMycT58A to between 5- and 100-fold the level in
naı¨ve ES cells, a similar range to that observed during early endo-
dermal differentiation, resulted in reduced Tcf7l1 mRNA levels
(Fig 6H). Downregulation of Tcf7l1 mRNA was lost when
A B
C D
Figure 3. Tcf7l1 null ES cells do not require CH to initiate endoderm differentiation programme.
A Assay of FoxA2 mRNA by RT–PCR in Tcf7l1 null cells on day 1 to 4 of differentiation without CH. Average and SD of three independent experiments.
B Gene expression analysis of endodermal associated genes by RT–PCR in control wild-type and Tcf7l1 null cells on day 4 of differentiation in the presence and absence
of 3 lM CH. Average and SD of three independent experiments.
C FoxA2 (green) and Oct4 (red) immunostaining of Tcf7l1 null ES cells on day 4 of differentiation in the presence or absence of 3 lM CH. DAPI staining in blue. Scale
bars, 200 lm.
D Assay of CXCR4, Hhex and Sox17 mRNA by RT–PCR in control wild-type and Tcf7l1 null cells on day 6 of differentiation in the presence and absence of 3 lM CH.
Average and SD of three independent experiments.
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cMycT58A was induced to very high levels (over 200 fold). Myc is
involved in many cellular functions, and further complexity is
brought about by its function being both dose and context depen-
dent (Murphy et al, 2008). Therefore, the effects of overexpression
of Myc during endoderm differentiation are uncertain since this
will affect processes not relevant to the normal differentiation
process. Our focus therefore was to express Myc ectopically at
levels equivalent to those found during endodermal differentiation.
Importantly, induction of physiological levels of cMycT58A during
differentiation resulted in a significant reduction in Tcf7l1 expres-
sion, without requirement for CH (Fig 6I). This was also observed
in Ctnnb1 iT58A cell lines, confirming that the effect of Myc on
Tcf7l1 expression is independent of b-catenin (Fig EV4). Tcf7l1
protein levels were also reduced in response to cMycT58A induction
(Fig 6J), not as pronounced as with CH but similar to observations
in the Ctnnb1/ cells in response to CH and consistent with
parallel effects of GSK3 inhibition.
Collectively, these data support a model in which following CH
treatment distinct effectors, Myc and b-catenin, act in parallel to
ensure that Tcf7l1 function is rapidly extinguished, permitting
robust activation of FoxA2 in the presence of Nodal/Activin.
Tcf7l1 is a direct target of cMyc
The ability of cMycT58A to reduce Tcf7l1 transcription suggested
that the Tcf7l1 gene could be a direct target of cMyc. The genomic
region upstream of the Tcf7l1 transcriptional start site (TSS) was
examined for cMyc-binding motifs, and a cluster of 9 non-
consensus cMyc-binding motifs (CATGTG or CAGGAG) was found
within 3 kb of the TSS (Fig 7A).
ChIP-PCR was used to investigate cMyc binding to the Tcf7l1
proximal promoter. Binding of cMyc to the Tcf7l1 promoter was low
in ES cells and during differentiation in the absence of CH (Figs 7B
and EV5). CH induced a significant increase in binding of cMyc at
A B
C
E
D
Figure 4. Induction of FoxA2 alleviates the requirement for CH.
A Assay of FoxA2 mRNA by RT–PCR in FoxA2-Tet ES cell lines 48 h after treatment with the indicated dose of DOX. Results from two independently derived clonal lines.
B FoxA2 immunostaining of FoxA2-Tet ES cells 48 h after DOX treatment. Left, no DOX control. Middle and right, 10 ng/ml DOX. DAPI staining shown in blue. Right
panel shows middle image without DAPI signal. Scale bars, 200 lm.
C Assay of FoxA2 and CXCR4 mRNA by RT–PCR on day 3 of differentiation with DOX at the indicated dose. Results from two independently derived clonal lines.
D Assay of Sox17 mRNA by RT–PCR on day 7 of differentiation with the addition of 3 lM CH and/or 10 ng/ml DOX at the indicated time points (in days). Results from
two independently derived clonal lines.
E Sox17 immunostaining of FoxA2-Tet ES cells at day 7 of differentiation in the presence or absence of 10 ng/ml DOX and the presence and absence of 3 lM CH as
indicated. Far right panel shows image to its left without DAPI. Scale bars, 200 lm.
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a region in the Tcf7l1 proximal promoter, 350 to 750 bp upstream
of the TSS (region 8) (Fig 7B). cMyc binding to this region
was ablated following addition of the cMyc inhibitor 10058-F4
(Fig 7C).
The potent effect of cMyc on FoxA2 expression during differenti-
ation prompted us to investigate whether, in addition to Tcf7l1
repression, cMyc was also having a direct effect on FoxA2 expres-
sion. Several Myc binding motifs were identified in the FoxA2
promoter, and ChIP-PCR was used to analyse cMyc binding to these
regions. In contrast to the Tcf7l1 promoter, no significant increase
in binding of cMyc to the FoxA2 promoter was observed in response
to CH (Fig EV5). These data are not supportive of FoxA2 being a
direct target of cMyc. However, in the absence of genomewide ChIP
data during differentiation, we cannot rule out the possibility that
cMyc may also act directly on FoxA2 and contribute to its induction
when Tcf7l1 is repressed.
cMyc/Max forms a repressive complex upon binding of Miz1
(Staller et al, 2001), and we identified a putative Miz1 binding motif
within the cMyc binding domain in the Tcf7l1 proximal promoter
(Wolf et al, 2013; Barrilleaux et al, 2014) (Fig 7A). In addition,
promoters repressed by Myc are known to be enriched for SP1 sites,
which bind both Myc and Miz1 (Walz et al, 2014). SP1 sites are also
present in the Tcf7l1 proximal promoter around region 8 (Fig 7A).
Miz1 is expressed in ES cells and during the initial stages of
endodermal differentiation (Fig 7D). ChIP-PCR was used to deter-
mine whether Miz1 binds to the Tcf7l1 proximal promoter. Indeed,
we find that Miz1 was bound to the Tcf7l1 promoter at day 2 of dif-
ferentiation and co-localised to the same region as cMyc (Fig 7E). In
contrast to cMyc, Miz1 binding to this region was not dependent on
CH, suggesting that Miz1 may be pre-bound prior to recruitment of
cMyc at the onset of differentiation (Fig EV5).
In summary, we find that CH-induced GSK3 inhibition during dif-
ferentiation results in increased binding of cMyc to a Miz1 bound
site in the Tcf7l1 proximal promoter, and this is associated with
repressed Tcf7l1 transcription, which in turn relieves the repression
of FoxA2.
Discussion
In this study, we explored in vitro specification of naı¨ve ES cells to
definitive endoderm and deconvoluted underlying signalling and
transcriptional processes. We uncovered sequential and mechanisti-
cally distinct effects of GSK3 inhibition. Downstream of GSK3 inhibi-
tion dual effector mechanisms initially converge to attenuate Tcf7l.
Consequent to reduction of Tcf7l1, transcription of FoxA2 is de-
repressed. FoxA proteins are pioneer factors and have an ability to
bind to and open up compacted chromatin in preparation for gene
activity (Zaret & Carroll, 2011; Li et al, 2012). Thus, FoxA2 likely
enables a cascade of downstream transcriptional and epigenetic
changes that drives subsequent endoderm commitment, further
facilitated by GSK3 inhibition stimulating canonical Wnt/b-catenin
activity (Fig 8).
Tcf7l1 is a member of the Tcf/Lef family of transcription factors
and has a well-established role in mammals as a transcriptional
repressor (Merrill et al, 2004; Pereira et al, 2006; Wray et al, 2011;
Hoffman et al, 2013). Genetic ablation of Tcf7l1 leads to an
expanded expression domain for FoxA2 in the mouse embryo
A B
C D
Figure 5. Suppression of GSK3 activity reduces Tcf7l1 and induces FoxA2 through both b-catenin-dependent and b-catenin-independent pathways.
A TOPFlash reporter activity following differentiation for 3 days in 3 lM CH or 100 ng/ml (W100) or 200 ng/ml (W200) recombinant Wnt3a plus 500 ng/ml
recombinant R-spondin-1. Relative luciferase units are normalised to FOPFlash. Average and SD of three independent experiments.
B Assay of Tcf7l1 and FoxA2 mRNA by RT–PCR at day 2 of differentiation in the presence or absence of 3 lM CH or recombinant Wnt3a (200 ng/ml plus 500 ng/ml
R-spondin-1 (WR)). Average and SD of three independent experiments. **P < 0.01.
C Assay of Tcf7l1 and FoxA2 mRNA by RT–PCR in Ctnnb1 null cells at day 1 and 3 of differentiation in the absence or presence of 3 lM CH. Average and SD of three
independent experiments.
D Immunoblot for Tcf7l1 in Ctnnb1 null cells during the first 3 days of differentiation in the absence () or presence (+) of 3 lM CH. Results from two independent,
clonally derived Ctnnb1 null ES cell lines are shown. Tubulin was used as a loading control.
Source data are available online for this figure.
ª 2015 The Authors The EMBO Journal
Gillian Morrison et al Tcf7l1 is a roadblock to endoderm specification The EMBO Journal
7
Published online: December 16, 2015 
(Merrill et al, 2004), consistent with our in vitro findings that
abrogation of Tcf7l1 is a critical step in enabling activation of FoxA2
expression.
How does GSK3 inhibition suppress Tcf7l1 activity? GSK3 is a
central component in the b-catenin destruction complex and its
inhibition is widely used as a mimetic of canonical Wnt pathway
activation. Direct protein–protein interaction between b-catenin and
Tcf7l1 reduces DNA binding (Shy et al, 2013). However, we found
that Wnt signalling only partially recapitulates the effects of GSK
inhibition and cannot account for the prominent reduction in Tcf7l1
mRNA. This prompted us to search for additional downstream
effectors involved in endoderm specification.
GSK3 phosphorylates cMyc and targets it for proteasomal
degradation. Accordingly, CH stabilises cMyc during early
A B C
D E F
G
J
H I
Figure 6. cMyc protein is stabilised by GSK3 inhibition and reduces Tcf7l1 expression independently of b-catenin.
A Assay of cMyc mRNA by RT–PCR in wild-type ES cells at day 1 to 3 of differentiation. Average and SD of three independent experiments.
B Immunoblot for total cMyc and phosphor-Ser62 (pSer62) cMyc during the first 3 days of differentiation in the absence () or presence (+) of 3 lM CH. Tubulin was
used as a loading control.
C, D Immunoblot for the destabilised form of cMyc protein (pThr58) during the first 3 days of differentiation in the absence () or presence (+) of 3 lM CH in wild-type
(C) and Ctnnb1 null (D) cells. Tubulin was used as a loading control.
E Assay of Tcf7l1 mRNA by RT–PCR in wild-type cells at day 2 of differentiation in the presence or absence of a small-molecule inhibitor of cMyc (cMyc inhibitor II;
Myci). Treatment with Myc inhibitor 10058-F4 (Sigma) generated similar results (data not shown). Average and SD of three independent experiments. **P = 0.0002.
F Assay of Tcf7l1 and FoxA2 mRNA by RT–PCR in cMyc null/nMyc heterozygous cells (C/;N+/) and floxed parental cells (cMycfl/fl;nMycfl/fl; control) at day 3 of
differentiation in the presence or absence of 3 lM CH. Average and SD of four or six independent experiments. Tcf7l1: *P = 0.01, FoxA2: *P = 0.034.
G FoxA2 immunostaining of control and cMyc null/nMyc heterozygous (cMyc/;nMyc+/) cells at day 3 of differentiation in the presence of 3 lM CH. Scale bar,
200 lm.
H Assay of cMyc and Tcf7l1 mRNA by RT–PCR in cMycT58A-inducible cell lines (icMycT58A) 24 h after DOX treatment. Average of two independent experiments.
I Assay of Tcf7l1 mRNA by RT–PCR in icMycT58A clone 1 cell line at day 3 of differentiation in the absence of 3 lM CH following cMyc induction with 10 ng/ml DOX.
Average and SD of 3 independent experiments. **P = 0.007.
J Immunoblot for cMyc and Tcf7l1 in icMycT58A clone 1 cell line 48 h after DOX induction at 10 ng/ml. Tubulin was used as a loading control.
Source data are available online for this figure.
The EMBO Journal ª 2015 The Authors
The EMBO Journal Tcf7l1 is a roadblock to endoderm specification Gillian Morrison et al
8
Published online: December 16, 2015 
endoderm differentiation. Our results demonstrate that this leads
to a pronounced reduction in Tcf7l1 expression associated with
increased binding of cMyc to the Tcf7l1 proximal promoter.
Miz1, a co-repressor with cMyc, is also significantly bound to
this region suggesting Myc/Miz function together to directly
repress Tcf7l1. It is also possible that cMyc has additional, indi-
rect effects on Tcf7l1 expression, for example by activating other
transcriptional or chromatin repressors. Thus, we propose that
inhibition of GSK3 activity attenuates Tcf7l1 both transcription-
ally (Myc repression) and post-transcriptionally (b-catenin-
mediated protein degradation) (Shy et al, 2013). Together, these
effects relieve Tcf7l1 repression of FoxA2 to permit timely and
robust endodermal specification.
ES cells cultured in the presence of serum are heterogeneous and
poised for differentiation. They express cMyc at significantly higher
levels than ground state ES cells (Ying et al, 2008; Marks et al,
2012). The requirement to increase the activity of cMyc at the onset
of endodermal differentiation may therefore be masked in serum
culture. This study starting from ES cells in a state closely resem-
bling the pre-implantation epiblast (Boroviak et al, 2014) and apply-
ing defined conditions for differentiation has provided fresh insight
into the requirements for endoderm induction.
Our findings also clarify the roles of Wnt/b-catenin signalling in
endoderm specification. Wnt signalling certainly contributes to
endoderm specification, but it is neither necessary nor sufficient to
induce FoxA2 activation and initiate endodermal cell fate. Our
findings indicate that the major contribution of Wnt signalling is in
A B C
D E
Figure 7. cMyc binds to the Tcf7l1 genomic locus in response to CH.
A Schematic representation of the genomic region upstream of the Tcf7l1 transcriptional start site (TSS). Red lines indicate PCR amplicons designed to span the
putative Myc binding sites (1–7 and 9) or putative Miz1 binding site (8).
B ChIP for cMyc performed in wild-type ES cells differentiated for 2 days in the absence or presence of 3 lM CH. qPCR was carried out for the regions indicated in (A).
Average and SD for five independent experiments, *P = 0.028.
C ChIP for cMyc performed in wild-type ES cells differentiated for 2 days in the presence of 3 lM CH plus or minus Myc inhibitor 10058-F4. qPCR was carried out for
the regions indicated in (A). Average and SD for three independent experiments, *P = 0.026.
D Assay of Miz1 mRNA by RT–PCR for the first 3 days of differentiation in the presence or absence of 3 lM CH. Average and SD of three independent experiments.
E ChIP for Miz1 or IgG control performed in E14 ES cells differentiated for 2 days in presence of 3 lM CH. qPCR was carried out for the regions indicated in (A). Average
and SD for five independent experiments, *P = 0.0015.
Figure 8. Multiple mediators of GSK3 inhibition converge on Tcf7l1 to lift
the roadblock to endoderm specification.
Inhibition of GSK3 stabilises cMyc and b-catenin protein levels. cMyc and
b-catenin decrease Tcf7l1 protein levels resulting in the de-repression of FoxA2,
allowing responsiveness to endoderm inducers such as Nodal/Activin.
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induction of the later endodermal marker Sox17 and consolidation
of the endoderm gene regulatory network.
FoxA2 transcriptional activation lies downstream of Nodal signal-
ling (Hoodless et al, 2001; Xi et al, 2011), and consistent with this,
Activin A was critical in addition to CH for efficient endodermal
differentiation. Reduced levels and activity of Tcf7l1 remove a
roadblock to Activin/Nodal-mediated activation of FoxA2. Thus,
conjoint activity of three core effectors—cMyc, Wnt/b-catenin and
Activin/Nodal—directs early endoderm induction.
Abnormal expression of TCF7L1 and FOXA2 is associated with
multiple aggressive human malignancies of endodermal origin
(Song et al, 2010; Liu et al, 2012; Wang et al, 2014). Thus, it may
be of interest to explore how the molecular pathways uncovered in
this study operate in human cancers. For example, does dysregula-
tion of TCF7L1/FOXA2 lead to loss of differentiated features, a hall-
mark of anaplastic tumours? Related to this, FoxA2 is known to
function in the balance between EMT and MET (Song et al, 2010).
In conclusion, our findings reveal that Tcf7l1 is a barrier to defi-
nitive endoderm specification, acting to directly block induction of
the pioneer transcription factor, FoxA2. cMyc and b-catenin operate
downstream of GSK3 inhibition to reduce Tcf7l1 transcription and
activity, respectively. This explains the potent effects of GSK3 inhi-
bition in promoting endoderm lineage specification from the naı¨ve
state and highlights the developmental switch in Tcf7l1 repressor
function from promoting collapse of naı¨ve pluripotency to constrain-
ing lineage segregation (Hoffman et al, 2013).
Materials and Methods
Cell lines, culture and differentiation
Mouse ES cells (E14Tg2a (Smith & Hooper, 1987) and derivatives
(see below), 129/Bl6 (derived in-house), CGR8 (Mountford et al,
1994), NOD (Nichols et al, 2009), Tcf7l1 null (Merrill et al, 2004;
Guo et al, 2011), Ctnnb1 null (Wray et al, 2011), HexRedStar
(Morrison et al, 2008), cMycfl/fl;nMycfl/fl, cMyc null;nMyc het
(Scognamiglio et al, manuscript submitted)) were cultured
feeder-free on plastic coated with 0.1% gelatin (Sigma, G1890) in
NDiffTM N2B27 base medium (Stem Cell Sciences Ltd, SCS-SF-NB-
02) supplemented with small-molecule inhibitors PD03 (1 lM,
PD0325901) and CH (3 lM, CHIR99021) (2i media). Ctnnb1 null,
cMycfl/fl;nMycfl/fl and cMyc null;nMyc het cell lines were cultured in
2i media supplemented with 100 units/ml leukaemia inhibitory
factor (LIF). Cells were re-plated every 2–3 days at a split ratio of 1
in 6 following dissociation with Accutase (PAA, L11-007).
Alternative Gsk3 inhibitors were generously gifted by Pfizer:
Gsk3i1: CE-323571 (750 nM), Gsk3i2: PF-00179382 (250 nM),
Gsk3i3: PF-04446208 (100 nM), Gsk3i4: PF-00179388 (100 nM) and
Gsk3i5: PF-04584015 (150 nM) (Wray et al, 2011).
For endodermal differentiation, cells were seeded on plastic
coated with 0.1% gelatin at 3 × 103 cells/cm2 in NDiffTM N2B27 base
medium supplemented with Activin A (20 ng/ml) (prepared in-
house), Fgf4 (10 ng/ml) (R&D Systems, 235-F4), heparin (1 lg/ml)
(Sigma), PI3 kinase inhibitor PI103 (100 nM) (Cayman Chemicals,
10009209) and CHIR99021 (3 lM). After 48 h, the media was changed
to SF5 (DMEM:F12 plus 0.5% N2 (Invitrogen, 17502048), 1% B27
minus vitamin A (Invitrogen, 12587-010), 1 mM L-glutamine,
0.1 mM 2-mercaptoethanol (Sigma, M7522), 0.05% BSA) supple-
mented with Activin A (20 ng/ml), Fgf4 (10 ng/ml), heparin (1 lg/
ml), EGF (10 ng/ml) (Peprotech, AF-100-15), PI103 (100 nM) and
CHIR99021 (3 lM). This media was changed every 48 h for the next
5 days. Additional reagents tested in the differentiation regime:
recombinant Wnt3a (R&D Systems, 1324-WN), R-spondin-1 (R&D
Systems, 3474-RS), cMyc inhibitor II (cMyci) (Calbiochem, 475957),
cMyc inhibitor 10058-F4 (Sigma, F3680).
Pancreatic progenitors cells (Morrison et al, 2008) were
produced following endodermal differentiation by culturing in SF5
media supplemented with KAAD-cyclopamine (Calbiochem,
239804), 0.25 lM all-trans retinoic acid (Sigma, 95152) and
50 ng/ml Noggin (Peprotech, 250-38) for additional 3–5 days.
Hepatic progenitors (D’Amour et al, 2005) were generated by cultur-
ing in NDiffTM N2B27 base medium supplemented with ascorbic acid
(0.5 lM) (Sigma, A4403), monothiolglycerol (4.5 × 104 M)
(Sigma, M6145), BMP4 (50 ng/ml) (prepared in-house), FGF2
(10 ng/ml), (prepared in-house), VEGF (10 ng/ml) (R+D, 293-VE),
HGF (20 ng/ml) (R+D, 2207-HG-025) for additional 5 days.
Generation of Dox-inducible cell lines
Mouse FoxA2 and cMyc open reading frame sequences were
inserted downstream of a third-generation Tet-responsive promoter
(PTRE3Gpromoter, Clontech) using Gateway cloning (Invitrogen).
The cMyc T58A variant was generated by excising a 680-bp KasI/
SbfI fragment from the wild-type cMyc coding sequence and
replacing it with a synthesised DNA fragment encoding a thre-
onine to alanine change at position 58 (GeneArt Strings, Invitro-
gen). The PTRE3G-FoxA2 and PTRE3G-cMyc
T58A constructs were used
in combination with the pCAG Tet-On 3G Transactivator (Clon-
tech) construct. Piggybac sites were included in the responder and
activator constructs. Responder, activator and pBase constructs
were transfected into ES cells using Lipofectamine 2000 (Invitro-
gen). Cells were selected on ZeocinTM (InvivoGen) and clonal lines
derived. Doxycycline hydrochloride (Sigma, D3447) was added as
indicated. In some cases, ES cells were maintained in serum
(Sigma) and Lif (prepared in-house) for transfection and clonal
expansion.
Flow cytometry
For CXCR4 and PDGFRa analysis, cells were dissociated with PBS-
based cell dissociation buffer (Gibco), resuspended in PBS/1% rat
serum and incubated with APC-conjugated CXCR4 antibody or APC-
conjugated PDGFRa antibody (details of antibodies used are listed
in Table EV1) and analysed on a CyAn (Beckman Coulter). DAPI
counterstaining was used to exclude dead cells.
Western immunoblotting
Western blots were carried out using the following antibodies at the
indicated dilutions: aTcf7l1 (Santa Cruz sc8635, 1:500), acMyc
(Santa Cruz sc42, 1:500), ap-cMycSer62 (Abcam ab185656,
1:1,000), ap-cMycThr58 (Santa Cruz sc135647, 1:500), alpha-
tubulin (Abcam ab126165, 1:1,000), agoat HRP (Abcam ab6741,
1:2,000), amouse HRP (Abcam ab6728, 1:2,000), and arabbit HRP
(Abcam ab16284, 1:2,000).
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Chromatin immunoprecipitation
Embryonic stem cells and differentiating cells were fixed for 10 min
in 1% formaldehyde, quenched with glycine, washed in ice-cold
PBS and incubated for 20 min at 4°C with rotation in swelling buffer
(5 mM HEPES at pH 8.25, 85mM KCl and 0.5% NP-40). Nuclei were
pelleted in a microfuge and resuspended in lysis buffer (50 mM Tris
at pH 8.0, 10 mM EDTA and 1% SDS) at 4°C for 10 min. Lysates
were sonicated to obtain a DNA fragment size of between 200 and
500 base pairs and diluted 1:10 in chromatin immunoprecipitation
dilution buffer (50mM Tris–HCl at pH 8.0, 167mM NaCl, 1.1%
Triton X-100 and 0.11% Na deoxycholate), pre-cleared for 2 h at
4°C with protein-G Sepharose beads (Amersham) and isotype
control antibody and incubated overnight at 4°C with 2 lg Tcf3 anti-
body (Santa Cruz, sc8635), 2 lg Miz1 antibody (Santa Cruz H-190,
sc-22837), 5 lg cMyc antibody (R&D Systems, AF3696) or control
antibodies normal goat IgG (R&D Systems, AB-108-C) and normal
rabbit IgG (R&D Systems, AB-105-C). Lysates were then incubated
for 45min at 4°C with blocked protein-G Sepharose beads, and
beads were washed twice each in RIPA/150 mM NaCl (RIPA;
50 mM Tris–HCl at pH 8.0, 150 mM NaCl, 1mM EDTA at pH 8.0,
1% Triton X-100, 0.1% SDS and 0.1% Na deoxycholate), taking a
sample of supernatant after the first centrifugation for input DNA
sample, then once in RIPA/500mM NaCl, once in LiCl wash
buffer (10 mM Tris–HCl pH 8.0, 250 mM LiCl, 1 mM EDTA) and
twice in ice-cold Tris-EDTA buffer. Chromatin was eluted for 20
min at 37°C in elution buffer (10 mM Tris–HCl pH 8.0, 1 mM
EDTA pH 8.0, 0.1 M NaHCO3, 1% SDS). Chromatin was analysed
by SYBR green real-time PCR (see Table EV2). Per cent input was
calculated using standard procedures (http://www.thermofisher.
com/us/en/home/life-science/epigenetics-noncoding-rna-research/
chromatin-remodeling/chromatin-immunoprecipitation-chip/chip-
analysis.html).
Gene expression analysis
RNA was isolated using the RNeasy Kit (Qiagen), reverse-
transcribed using SuperScript III (Life Technologies) according to
the manufacturer’s instructions and analysed by real-time PCR using
TaqMan Fast Universal Master Mix and TaqMan probes (Applied
Biosystems), the Universal Probe Library system (UPL, Roche) or
SYBR green. Primers and UPL probe numbers are detailed in
Table EV2. A Taqman probe endogenous control (Gapdh, glycer-
aldehyde-3-phosphate dehydrogenase or beta actin) was used to
normalise expression.
Immunocytochemistry
Monolayer cells were washed in PBS, fixed in 4% paraformaldehyde
and permeabilised with PBS/0.1% Triton X-100. Details of antibod-
ies used are listed in Table EV1.
Luciferase assay
105 cells per well were transfected with 0.8 lg TOPFlash or
FOPFlash (Upstate) and 0.04 lg Renilla in 24-well plates. 24 h later,
cells were lysed and analysed using the dual luciferase kit
(Promega) according to the manufacturer’s protocol.
Statistical analysis
Paired-sample t-tests (two-tailed) were used to determine significant
difference between data sets of n = 3 or above.
Expanded View for this article is available online.
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